DMN:FRA
Diamyd Medical AB
၀.၀၆၃ €
arrow_downward
-၀.၆၃%(-၀.၀၀၀၄၀) 1D
နို ၁၃, GMT+၁ ၂၂:၀၀:၀၀ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
၀.၀၆ €
High
၀.၀၆ €
Low
၀.၀၆ €
Mkt. cap
၁၃.၉၅ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၂
Open
၀.၀၆ €
High
၀.၀၆ €
Low
၀.၀၆ €
Mkt. cap
၁၃.၉၅ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၂
News stories
From web sources and news partners
Seoul Economic Daily
·
ပြီးခဲ့သည့် ၂၂ မိနစ်
Doosan Halts U.S. Unit's Nasdaq Listing as Dual-Listing Curbs Bite
www.tokenpost.com
·
ပြီးခဲ့သည့် ၁ နာရီ
Ava Labs Says Avalanche Will Provide Ledger for NYSE-Linked Securities Venue
Traders Union
·
ပြီးခဲ့သည့် ၁ နာရီ
Gate.io announces indicative USDT subscriptions for Anthropic IPO ahead of Nasdaq listing
AP News
·
ပြီးခဲ့သည့် ၁ ရက်
Microsoft outage shows the risks of relying on a single technology provider for essential services
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB